IP Journal of Urology, Nephrology and Hepatology Science

---

Liver fibrosis and cirrhosis mutations can be treated with stem cells therapy followed by circulating innate immune cells trnasfusion

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Shaikh Mahmood*

Volume : 4, Issue : 4, Year : 2021

Article Page : 95-100

Suggest article by email

---

Abstract

Patients with keratin gene mutation have fibrous deposits in their livers than individual without the mutations. These deposits impair liver function, leading to liver cirrhosis. In individual with an associated keratin gene mutation, the risk of developing cryptogenic cirrhosis appears to have an autosomal dominant pattern of inheritance means that one copy of an altered gene in each cell is sufficient to increase the risk of developing cryptogenic cirrhosis. In these families, people inherit an increased risk of cryptogenic cirrhosis, not the disease itself. A gene mutation has been found to contribute to non-alcoholic fatty liver disease (NAFLD), a form of liver disease closely linked to obesity, in normal weight patients. Carries of the PNPLA3 mutant genotype were found to be a greater risk for NAFLD and health problems compared to non-carriers even when the carrier was not obese. This influence of weight status on the interaction between the mutant gene and NAFLD was clarified. Stem Cells Therapy is a suggestive procedure to substitute up to certain extent of the mutation. Meanwhile Circulating Innate Immune Cells can be transfused to increase the immunity of the effected patients.

Keywords: Liver Cirrhosis, Cryptogenetic Cirrhosis, Mutations, Stem Cells Therapy, Circulating Innate Immune Cell Transfusion

How to cite : Mahmood S, Liver fibrosis and cirrhosis mutations can be treated with stem cells therapy followed by circulating innate immune cells trnasfusion. J Urol Nephrol Hepatol Sci 2021;4(4):95-100

Copyright © 2021 by author(s) and J Urol Nephrol Hepatol Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)